Dipeptidyl peptidase IV: A cell surface peptidase involved in regulating T cell growth (Review)

International Journal of Molecular Medicine

Volumn 4, Issue 1, 1999, Pages 3-15

  Kähne, Thilo ^a   Lendeckel, Uwe ^a   Wrenger, Sabine ^a   Neubert, Klaus ^b   Ansorge, Siegfried ^a   Reinhold, Dirk ^a  

^a OTTO VON GUERICKE UNIVERSITY   (Germany)

^b MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

Author keywords

CD26; Dipeptidyl peptidase IV; Inhibitors; Signal transduction; T lymphocytes

Indexed keywords

ADENOSINE DEAMINASE; CYTOKINE; DIPEPTIDYL PEPTIDASE IV; ENZYME INHIBITOR; LIGAND;

AMINO ACID SEQUENCE; ANIMAL; BIOLOGICAL MODEL; BIOSYNTHESIS; CELL CYCLE; CELL DIVISION; CELL MEMBRANE; CHEMISTRY; CYTOLOGY; ENZYME SPECIFICITY; ENZYMOLOGY; GENETICS; HUMAN; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; METABOLISM; REVIEW; SIGNAL TRANSDUCTION; T LYMPHOCYTE;

ADENOSINE DEAMINASE; AMINO ACID SEQUENCE; ANIMALS; ANTIGENS, CD26; CELL CYCLE; CELL DIVISION; CELL MEMBRANE; CYTOKINES; ENZYME INHIBITORS; HUMANS; LIGANDS; LYMPHOCYTE ACTIVATION; MODELS, BIOLOGICAL; SIGNAL TRANSDUCTION; SUBSTRATE SPECIFICITY; T-LYMPHOCYTES;

EID: 0033159183     PISSN: 11073756     EISSN: None     Source Type: Journal    
DOI: 10.3892/ijmm.4.1.3     Document Type: Article

References (101)

1. Vanhoof G, Goossens F, De Meester I, Hendriks D and Scharpé S: Proline motifs in peptides and their biological progressing. FASEB J 9: 736-744, 1995.
2. Yaron A and Naider F: Proline-dependent structural and biological properties of peptides and proteins. Crit Rev Biochem Mol Biol 28: 31-81, 1993.
3. Fleischer B: CD26: a surface protease involved in T-cell activation. Immunol Today 15: 180-184, 1994.
4. Morimoto C and Schlossman SF: A key costimulatory molecule on CD4 memory T cells. Immunologist 2: 4-7, 1994.
5. Hegen M: CD26 workshop panel report. In: Leucocyte Typing VI. Kishimoto T and Kikutani H (eds). Garland Publishing, Inc., New York, London, pp478-481, 1997.
6. Abbott CA, Baker E, Sutherland GR and McCaughan GW: Genomic organization, exact localization, and tissue expression of the human CD26 (dipeptidyl peptidasc IV) gene (published erratum appears in Immunogenetics 42: 76, 1995). Immunogenetics 40: 331-338, 1994.
7. Hopsu-Havu KV and Glenner GG: A new dipeptide naphthylamidase hydrolyzing glycyl-prolyl-beta-naphthylamide. Histochcmie 7: 197-201, 1966.
8. Hopsu-Havu KV and Sarimo RS: Purification and characterization of an aminopcptidase hydrolyzing glycyl-proline-naphthylamide. Hoppe-Seylcr's Z Physiol Chem 348: 1540-1550, 1967.
9. Küllertz G, Fischer G, Schönberner H and Barth A: Untersuchungen der humanen DP IV. In: Dipeptidyl-Peptidasc IV Chemie, Biochemie und Physiologische Aspekte. Küllertz G, Oehme P and Barth A (eds). Akademie-Industrie-Komplex Arzeneimittelforschung, Berlin, pp61-104, 1981.
10. Stein H, Schwarting R and Niedobitek G: Cluster report: CD26. In: Leukocyte Typing IV. Knapp W, Dörken B, Gilks WR, et al (eds). Oxford University Press, Oxford, pp412-505, 1989.
11. Hegen M, Niedobitek C, Klein CE, Stein H and Fleischer B: The T cell triggering molecule Tpl03 is associated with dipeptidyl aminopeptidase IV activity. J Immunol 144: 2908-2914, 1990.
12. Reinhold D, Vetter RW, Mnich K, Bühling F, Lendeckel U, Born I, Faust J; Neubert K, Gollnick H and Ansorge S: Dipeptidyl peptidase IV (DP IV, CD26) is involved in regulation of DNA synthesis in human keratinocytes. FEBS Lett 428: 100-104, 1998.
13. Lojda Z: Studies on glycyl-proline naphthylamidase. I. Lymphocytes. Histochemistry 54: 299-309, 1977.
14. Ulmer AJ, Mattern T, Feller AC, Heymann E and Flad H: CD26 antigen is a surface dipeptidyl peptidase IV (DPPIV) as characterised by monoclonal antibodies clone TII-19-4-7 and 4EL1C1. Scand J Immunol 31: 429-435, 1990.
15. Mattem T, Flad H, Feller AC, Heymann E and Ulmer AJ: AntiDPP-IV and anti-Tal but not IOT 15 should be clustered in CDw26. In: Leukocyte Typing IV. Knapp W, Dörken B, Gilks WR, et al (eds). Oxford University Press, Oxford, New York, Tokyo, pp416, 1989.
16. Schön E, Demuth UH, Barth A and Ansorge S: Dipeptidyl peptidase IV of human lymphocytes. Evidence for specific hydrolysis of glycylprolin in T-lymphocytes. Biochem J 223: 255-258, 1984.
17. Bühling F, Junker U, Reinhold D, Neubert K, Jäger L and Ansorge S: Functional role of CD26 on human B lymphocytes. Immunol Lett 45: 47-51, 1995.
18. Bühling F, Kunz D, Reinhold D, Ulmer AJ, Ernst M, Flad H and Ansorge S: Expression and functional role of dipeptidyl peptidase IV on human natural killer cells. Nat Immun 13: 270-279, 1994.
19. Ansorge S, Schön E and Kunz-D: Membrane-bound peptidases of lymphocytes: functional implications. Biomed Biochem Acta 50: 799-807, 1991.
20. Schön E, Eichmann E, Grunow R, Jahn S, Kiessig ST, Volk H and Ansorge S: Dipeptidyl peptidase IV in human T lymphocytes. An approach to the role of a membrane peptidase in the immune system. Biomed Biochem Acta 45: 1523-1528, 1986.
21. Tiruppathi C, Miyamoto Y, Ganapathy V and Leibach FH: Genetic evidence for role of DPP IV in intestinal hydrolysis and assimilation of prolyl peptides. Am J Physiol 265: G81-G89, 1993.
22. Pauly RP, Rosche F, Wermann M, Mclntosh CHS, Pederson RA and Demuth HU: Investigation of glucose-dependent insulinotropic polypeptide-(1-42) and glucagon-like peptide-1-(7-36) degradation in vitro by dipeptidyl peptidase IV using matrix-assisted laser desorption/ionization time of flight mass spectrometry - a novel kinetic approach. J Biol Chem 271: 23222-23229, 1996.
23. Scharpé S, De Meester I, Hendriks D, Vanhoof G, van Sande M and Vriend G: Protcases and their inhibitors: today and tomorrow. Biochimie 73: 121-126, 1991.
24. Hoffmann T, Faust J, Neubert K and Ansorge S: Dipeptidyl peptidase IV (CD26) and aminopcptidase N (CD13) catalyzed hydrolysis of cytokines and peptides with N-terminal cytokine sequences. FEBS Lett 336: 61-64, 1993.
25. Oravecz T, Pall M, Roderiquez G, Gorrell MD, Ditto M, Nguyen NY, Boykins R, Unsworth E and Norcross MA: Regulation of the receptor specificity and function of the chemokine RANTES (regulated on activation, normal T cell expressed and secreted) by dipeptidyl peptidase IV (CD26)mediated cleavage. J Exp Mcd 186: 1865-1872, 1997.
26. Schols D, Proost P, Struyf S, Wuyts A, De Meester I, Scharpé S, van Damme J and De Clercq E: CD26-processed RANTES (3-68), but not intact RANTES, has potent anti-HIV-1 activity. Antiviral Res 39: 175-187, 1998.
27. Struyi S, DC Meester I, Scharpé S, Lenaerts JP, Menten P, Wang JM, Proost P and van Damme J: Natural truncation of RANTES abolishes signaling through the CC chemokine receptors CCR1 and CCR3, impairs its chemotactic potency and generates a CC chemokine inhibitor. Eur J Immunol 28: 1262-1271, 1998.
28. Proost P, De Meester I, Schols D, Struyf S, Lambeir AM, Wuyts A, Opdenakker G, De Clercq E, Scharpé S and van Damme J: Amino-terminal truncation of chemokines by CD26/ dipcptidylpeptidasc IV - conversion of RANTES into a potent inhibitor of monocyte chemotaxis and HIV-1-infection. J Biol Chem 273: 7222-7227, 1998.
29. Hanski C, Huhle T and Rcutter W: Involvement of plasma membrane dipeptidyl peptidase IV in fibronectin-mediated adhesion of cells on collagen. Biol Chem Hoppe-Seyler 366: 1169-1176, 1985.
30. Hanski C, Huhle T, Gossrau R and Reutter W: Direct evidence for the binding of rat liver DPP IV to collagen in vitro. Exp Cell Res 178: 64-72, 1988.
31. Löster K, Zeilinger K, Schuppan D and Reutter W: The cysteine rich region of dipeptidyl peptidase IV (CD26) is the collagenbinding site. Biochem Biophys Res Commun 217: 341-348, 1995.
32. Kameoka J, Tanaka T, Nojima Y, Schlossman SF and Morimoto C: Direct association of adenosine deaminase with a T cell activation antigen, CD26. Science 261: 466-469, 1993.
33. Morrison ME, Vijayasaradhi S, Engelstein D, Albino AP and Houghton AN: A marker for neoplastic progression of human melanocytes is a cell surface ectopeptidase. J Exp Med 177: 1135-1143, 1993.
34. Torimoto Y, Dang NH, Vivier E, Tanaka T, Schlossman SF and Morimoto C: Coassociation of CD26 (dipeptidyl peptidase IV) with CD45 on the surface of human T lymphocytes. J Immunol 147: 2514-2517, 1991.
35. + cells. Science 262: 2045-2050, 1993.
36. Balter M: Skepticism greets HIV coreceptor. Science 262: 843-844, 1993.
37. Broder CC, Nussbaum O, Gutheil WG, Bachovin WW and Berger EA: CD26 antigen and HIV fusion? Science 264: 1156-1159, 1994.
38. Lazaro I, Naniche D, Signoret N, Bernard AM, Marquet D, Klatzmann D, Dragic T, Alizon M and Sattcntau Q: Factors involved in entry of the human immunodeficiency virus type 1 into permissive cells: lack of evidence of a role for CD26. J Virol 68: 6535-6546, 1994.
39. Morimoto C, Lord CI, Zhang C, Duke-Cohan JS, Letvin NL and Schlossman SF: Role of CD26/dipeptidyl peptidase IV in human immunodeficiency virus type 1 infection and apoptosis. Proc Natl Acad Sci USA 91: 9960-9964, 1994.
40. + T tells expressing relatively high levels of CD26. Exp Cell Res 241: 352-362, 1998.
41. Gutheil WG, Subramanyam M, Flentkc GR, Sanford DG, Munoz E, Huber BT and Bachovchin WW: Human immunodeficiency virus 1 Tat binds to dipeptidyl aminopeptidase IV (CD26): a possible mechanism for Tat's immunosuppressive activity. Proc Natl Acad Sci USA 91: 6594-6598, 1994.
42. Wrenger S, Hoffmann T, Faust J, Mrestani-Klaus C, Brandt W, Neubert K, Kraft M, Olek S, Frank R, Ansorge S and Reinhold D: The N-terminal structure of HIV-1 Tat is required for suppression of CD26-dependent T cell growth. J Biol Chem 272: 30283-30288, 1997.
43. Dang NH, Torimoto Y, Deusch K, Schlossman SF and Morimoto C: Comitogenic effect of solid-phase immobilized anti-1F7 on human CD4 T cell activation via-CD3 and CD2 pathways.J Immunol 144: 4092-4100, 1990.
44. Dang NH, Torimoto Y, Sugita K, Daley JF, Show P, Porado C, Schlossman SF and Morimoto C: Cell surface modulation of CD26 by anti-1F7 monoclonal antibody. Analysis of surface expression and human T cell activation. J Immunol 145: 3963-3971, 1990.
45. Dang NH, Torimoto Y, Shimamura K, Tanaka T, Dalcy JF, Schlossman SF and Morimoto C: 1F7 (CD26): a marker of thymic maturation involved in the differential regulation of the CD3 and CD2 pathways of human thymocyte activation. J Immunol 147: 2825-2832, 1991.
46. Schön E, Born I, Demuth H-U, Faust J, Neubert K, Steinmetzer T, Barth A and Ansorge S: Dipeptidyl peptidase IV in the immune system. Effects of specific enzyme inhibitors on activity of dipeptidyl peptidase IV and proliferation of human lymphocytes. Biol Chem Hoppe-Seyler 372: 305-311, 1991.
47. Schön E, Demulh H-U, Eichmann E, Horst H, Kömer I-J, Kopp J, Mattern T, Neubert K, Noll F, Ulmer JA, Barth A and Ansorge S: Dipeptidyl peptidase IV in human T lymphocytes impaired induction of interleukin 2 and gamma Interferon due to specific inhibition of dipeptidyl peptidase IV. Scand J Immunol 29: 127-132, 1989.
48. Schön E, Jahn S, Kiessig ST, Demuth H-U, Neubert K, Barth A, von Baehr R and Ansorge S: The role of dipeptidyl peptidase IV in human T lymphocyte activation. Inhibitors and antibodies against dipeptidyl peptidase IV suppress lymphocyte proliferation and immunoglobulin synthesis in vitro. Eur J Immunol 17: 1821-1826, 1987.
49. Torimoto Y, Dang NH, Tanaka T, Prado C, Schlossman SF and Morimoto C: Biochemical characterization of CD26 (dipeptidyl peptidase IV): functional comparison of distinct epitopes recognized by various anti-CD26 monoclonal antibodies. Mol Immunol 29: 183-192, 1992.
50. Mittrücker H, Steeg C, Malissen B and Fleischer B: The cytoplasmic tail of the T cell receptor zeta-chain is required for signaling via CD26. Eur J Immunol 25: 295-297, 1995.
51. Morimoto C and Schlossman SF: The structure and function of CD26 in the T-cell immune response. Immunol Rev 161: 55-70, 1998.
52. Ansorge S, Bühling F, Kähne T, Lendeckel U, Reinhold D, Täger M and Wrenger S: CD26 dipeptidyl peptidase IV in lymphocyte growth regulation. Adv Exp Med Biol 421: 127-140, 1997.
53. Morimoto C, Torimoto Y, Levinson G, Rudd CE, Schrieber M, Dang NH, Letvin NL and Schlossman SF: 1F7, a novel cell surface molecule, involved in helper function of CD4 cells. J Immunol 143: 3430-3439, 1989.
54. Plana M, Vinas O, De la Calle-Martin O, Lozano F, InglesEsteve J, Romero M, Alberola-Ila J, Vilella R and Vives J: Induction of interleukin 2 and interferon-gamma and enhancement of IL-2 receptor expression by a CD26 monoclonal antibody. Eur J Immunol 21: 1085-1088, 1991.
55. Kähne T, Reinhold D, Lendeckel U, Bühling F, Täger M, Faust J, Neubert K and Ansorge S: The effect of anti-CD26 antibodies on DNA synthesis and cytokine production (IL-2, IL-10, IFN-gamma) depends on enzymatic activity of CD26/ DP IV. In: Leukocyte Typing VI. Kishimoto T (ed). Garland Publishing, New York, London, pp485-487, 1997.
56. Reinhold D, Kähne T, Täger M, Lendeckel U, Bühling F, Bank U, Wrenger S, Faust J, Neubert K and Ansorge S: The effect of anti-CD26 antibodies on DNA synthesis and cytokine production (IL-2, IL-10 and IFN-gamma) depends on enzymatic activity of DP IV CD26. Adv Exp Med Biol 421: 149-155, 1997.
57. Subramanyam M, Gutheil WG, Bachovchin WW and Huber BT: Mechanism of HIV-1 Tat induced inhibition of antigenspecific T cell rcsponsiveness. J Immunol 150: 2544-2553, 1993.
58. Reinhold D, Bank U, Bühling F, Neubert K, Mattern T, Ulmer AJ, Flad H and Ansorge S: Dipeptidyl peptidase IV (CD26) on human lymphocytes. Synthetic inhibitors of and antibodies against dipeptidyl peptidase IV suppress the proliferation of pokewccd mitogen-stimulated peripheral blood mononuclear cells and IL-2 and IL-6 production. Immunobiology 188: 403-414, 1993.
59. 1, in PWM-stimulated PBMC and T cells. Immunology 91: 354-360, 1997.
60. Korom S, De Meester I, Onodera K, Stadibauer THW, Borloo M, Lambeir AM and Kupiec-Weglinski JW: The effects of CD26/ DPP IV-targeted therapy on acute allosraft rejection. Transplant Proc 29: 1274-1275, 1997.
61. Flentke GR, Munoz E, Huber BT, Flaut AG, Kettner CA and Bachovchin WW: Inhibition of dipeptidyl aminopeptidase IV (DP-IV) by Xaa-boroPro dipeptides and use of these inhibitors to examine the role of DP-IV in T-cell function. Proc Natl Acad Sci USA 88: 1556-1559, 1991.
62. Tanaka S, Murakami T, Horikawa H, Sugiura M, Kawashima K and Sugita T: Suppression of arthritis by the inhibitors of dipeptidyl peptidase IV. Int J Immunopharmacol 19: 15-24, 1997.
63. Tanaka S, Murakami T, Nonaka N, Ohnuki T, Yamada M and Sugita T: Anti-arthritic effects of the novel dipeptidyl peptidase IV inhibitors TMC-2A and TSL-225. Immunopharmacology 40: 21-26, 1998.
64. Hoffmann T, Reinhold D, Kähne T, Faust J, Neubert K, Frank R and Ansorge S: Inhibition of dipeptidyl peptidase IV by antiDP IV antibodies and non-substrate X-X-Pro-oligopeptides ascertained by capillary electrophoresis. J Chromotogr A 716: 355-362, 1995.
65. Wrenger S, Reinhold D, Hoffmann T, Kraft M, Frank R, Faust J, Neubert K and Ansorge S: The N-terminal.X-X-Pro sequence of the HIV-1 Tat protein is important for the inhibition of the dipeptidyl peptidase IV (DP IV/CB26) and the suppression of mitogen-induced proliferation of human T cells. FEES Lett 383: 145-149, 1996.
66. Schön E and Ansorge S: Dipeptidyl peptidase IV in the immune system. Cytofluorimetric evidence for induction of the enzyme on activated T lymphocytes. Biol Chem Hoppe-Seyler 371: 699-705, 1990.
67. + T cell clones. J Neuroimmunol 87: 203-209, 1998.
68. Kasahara Y, Leroux-Roels G, Nakamura R and Chisari F: Glycylprolyl-diaminopeptidase in human leukocytes: selective occurrence in T lymphocytes and influence on the total serum enzyme activity. Clin Chim Acta 139: 295-302, 1984.
69. Kasahara K, Fujii N, Naka H and Nagatsu T: Multiple forms of glycylprolyl dipeptidyl-aminopeptidase (dipeptidylpeptidase IV) in human sera from patients with hepatitis. Biomed Res 3: 265-269, 1982.
70. Kasahara K, Fujii N, Mizukoshi M and Nagatsu T: Multiple forms of glycylprolyl aminopeptidase in serum and tissues. Jpn J Clin Chem 12: 89-93, 1983.
71. Krcpela E, Kraml J, Vicar J, Kadlecová L and Kasaffrek E: Demonstration of two molecular forms of dipeptidyl peptidase IV in normal human serum. Physiol Bohemoslov 32: 486-496, 1983.
72. Kähne T, Kröning H, Thiel U, Ulmer AJ, Flad H and Ansorge S: Alterations in structure and cellular localization of molecular forms of DP IV/CD26 during T cell activation. Cell Immunol 170: 63-70, 1996.
73. Fleischer B: A novel pathway of human T cell activation via a 103 kD T cell activation antigen. J Immunol 138: 1346-1350, 1987.
74. Munoz E, Blazquez MV, Maducno JA, Rubio G and Pena J: CD26 induces T-cell proliferation by tyrosine protein phosphorylation. Immunology 77: 43-50, 1992.
75. Kahne T and Ansorge S: Molecular heterogeneity of the T-cell activation and HIV coreceptor molecule CD26 (dipeptidyl peptidase IV): biochemical and cellular investigations. Eur J Cell Biol 40: 23-24, 1994.
76. Antonysamy MA, Moticka EJ and Ramkumar V: Adenosine acts as an endogenous modulator of IL-2-dependent proliferation of cytotoxic T lymphocytes. J Immunol 155: 2813-2821, 1995.
77. Barankiewicz J, Dosch HM and Cohen A: Extracellular nucleotide catabolism in human B and T lymphocytes. The source of adenosine production. J Biol Chem 263: 7094-7098, 1988.
78. Dong R-P, Kameoka J, Hegen M, Tanaka T, Xu Y, Schlossman SF and Morimoto C: Chartactcrization of adenosine deaminase binding to human CD26 on T cells and its biologic role in immune response. J Immunol 156: 1349-1355, 1996.
79. Gilbertsen RB: Adenosine and adenosine receptors in immune function. Minircview and meeting report. Agents Actions 22: 91-98, 1987.
80. Rathbone MP, Deforge S, Deluca B, Gabel B, Laurenssen C, Middlemiss P and Parkinson S: Purinergic stimulation of cell division and differentiation: mechanisms and pharmacological implications. Med Hypotheses 37: 213-219, 1992.
81. Cronstcin BN: Adenosine, an endogenous anti-inflammatory agent. J Appl Physiol 76: 5-13, 1994.
82. Von Bonin A, Hühn J and Fleischer B: Dipeptidyl-peptidase IV/ CD26 on T cells: analysis of an alternative T-cell activation pathway. Immunol Rev 161: 43-53, 1998.
83. Dong RP, Tachibana K, Hegen M, Munakata Y, Cho D, Schlossman SF and Morimoto C: Determination of adenosine deaminase binding domain on CD26 and its immunoregulatory effect on T cell activation. J Immunol 159: 6070-6076, 1997.
84. Valenzuela A, Blanco J, Callebaut C, Jacotot E, Lluis C, Hovanessian AG and Franco R: Adenosine deaminase binding to human CD26 is inhibited by HIV-1 envelope glycoprotein gp120 and viral particles. J Immunol 158: 3721-3729, 1997.
85. Callard R and Gearing A: The cytokine facts book. Academic Press, London, San Diego, 1994.
86. Hoffmann T, Neubert K and Ansorge S: Action of dipcptidyl peptidase IV (CD26) and aminopeptidase N (CD 13) on selected cytokines and cytokine peptides. Cyto Hemo Oncol Immunol III: 318-327, 1994.
87. Proost P, Struyf S, Schols D, Durinx C, Wuyts A, Lenaerts JP, De Clercq E, De Meester I and van Damme J: Processing by CD26/dipcptidyl-peptidase IV reduces the chemotactic and antiHIV-1 activity of stromal-cell-derived factor-Iα. FEBS Lett 432: 73-76, 1998.
88. Schön E, Mansfeld H-W, Demuth H-U, Barth A and Ansorge S: The dipeptidyl peptidasc IV, a membrane enzyme involved in the proliferation of T lymphocytes. Biomed Biochem Acta 44: K9-K15, 1985.
89. Reinhold D, Bank U, Bühling F, Kähne T, Kunz D, Faust J, Neubert K and Ansorge S: Inhibitors of dipeptidyl peptidase IV (DP IV, CD26) specifically suppress proliferation and modulate cytokine production of strongly CD26 expressing U937 cells. Immunobiology 192: 121-136, 1994.
90. Vivier I, Marguet D, Naquet P, Bonicel J, Black D, Xiao-Yan Li C, Bernard A-M, Gorvel J-P and Pierres M: Evidence that thymocyte-activating molecule is mouse CD26 (dipeptidyl peptidase IV). J Immunol 147: 447-454, 1991.
91. Reinhold D, Bank U, Bühling F, Täger M, Born I, Faust J, Neubert K and Ansorge S: Inhibitors of dipeptidyl peptidasc IV (DP IV, CD26) induces secretion of transforming growth factor-β1 (TGF-β1) in stimulated mouse splenocytes and thymocytes. Immunol Lett 58: 29-35, 1997.
92. Reinhold D, Bank U, Bühling F, Lendeckel U, Ulmer AJ, Flad H and Ansorge S: Transforming growth factor-β1 (TGF-β1) inhibits DNA synthesis of PWM stimulated PBMC via suppression of IL-2 and IL-6 production. Cytokines 6: 382-388, 1994.
93. Reinhold D, Bank U, Bühling F, Lendeckel U and Ansorge S: Transforming growth factor betal inhibits interleukin-10 mRNA expression and production in pokeweed mitogenstimulated peripheral blood mononuclear cells and T cells. J Interferon Cytokine Res 15: 685-690, 1995.
94. Sherr CJ and Roberts JM: Inhibitors of mammalian Gl cyclindependent kinases. Genes Dev 9: 1149-1163, 1995.
95. Polyak K, Lee MH, Erdjument-Bromage H, Koff A, Roberts JM, Tempst P and Massague J: Cloning of p27Kipl, a cyclindependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals. Cell 78: 59-66, 1994.
96. Polyak K, Kato JY, Solomon MJ, Sherr CJ, Massague J, Roberts JM and Koff A: p27Kipl, a cyclin-Cdk inhibitor, links transforming growth factor-beta and contact inhibition to cell cycle arrest. Genes Dev 8: 9-22, 1994.
97. Madueno JA, Munoz E, Blazquez V, Conzalez R, Aparicio P and Pena J: The CD26 antigen is coupled to protein tyrosine phosphorylation and implicated in CD16-mediated lysis in natural killer cells. Scand J Immunol 37: 425-429, 1993.
98. Hegen M, Kameoka J, Dong RP, Schlossman SF and Morimoto C: Cross-linking of CD26 by antibody induces tyrosine phosphorylation and activation of mitogen-activated protein kinase. Immunology 90: 257-264, 1997.
99. Kähne T, Neubert K, Faust J and Ansorge S: Early phosphorylation events induced by DPIV/CD26-specific inhibitors. Cell Immunol 189: 60-66, 1998.
100. lck. Immunol Lett 46: 189-193, 1995.
101. Lendeckel U, Arndt M, Frank K, Wex T and Ansorge S: Role of alanyl aminopeptidase in growth and function of human T cells. Int J Mol Med 4: 17-27, 1999.